
**Health informatics — Identification
of medicinal products — Data
elements and structures for the
unique identification and exchange
of regulated medicinal product
information**

*Informatique de santé — Identification des médicaments — Éléments
de données et structures pour l'identification unique et l'échange
d'informations sur les médicaments contrôlés*

get full document from standards.iteh.ai



Sample Document

get full document from standards.iteh.ai



COPYRIGHT PROTECTED DOCUMENT

© ISO 2017, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Ch. de Blandonnet 8 • CP 401
CH-1214 Vernier, Geneva, Switzerland
Tel. +41 22 749 01 11
Fax +41 22 749 09 47
copyright@iso.org
www.iso.org

Contents

Page

Foreword	vi
Introduction	vii
1 Scope	1
2 Normative references	1
3 Terms, definitions and abbreviated terms	2
4 Message exchange format	13
5 Conformance terminology and context as it relates to the ISO IDMP standards and corresponding IDMP technical specifications	14
6 Concepts required for the unique identification of Medicinal Products	14
6.1 General considerations	14
6.2 Authorised Medicinal Products	14
6.3 Investigational Medicinal Products	15
6.4 Concepts required for the unique identification of a Medicinal Product and the association with PhPID(s)	15
6.5 Concepts required for the unique identification of Medicinal Products and the association with the marketing authorisation number	15
6.6 Concepts required for the unique identification of Medicinal Products and the association with data carrier identifiers	16
7 Description of the information modelling principles and practices	17
7.1 General considerations	17
7.2 Conceptual overview diagrams	17
7.3 High-level diagrams	18
7.4 Detailed description diagrams	18
7.4.1 General	18
7.4.2 Relationships between classes	19
7.4.3 Attributes of classes	20
7.4.4 Generalised classes and patterns	20
7.4.5 Translation and language	20
8 Identifying characteristics for authorised Medicinal Products	20
8.1 Primary identifiers — General considerations	20
8.2 Medicinal Product Identifier (MPID)	21
8.2.1 General considerations	21
8.2.2 MPID code segments	21
8.3 Packaged Medicinal Product Identifier (PCID)	22
8.3.1 General considerations	22
8.3.2 Package description (PCID) code segment	23
8.4 Medicinal Product Batch Identifier (BAID1)	23
8.5 Medicinal Product Batch Identifier (BAID2)	23
9 Information for an authorised Medicinal Product	24
9.1 Authorised Medicinal Product — Information overview	24
9.1.1 General	24
9.1.2 Medicinal Product	24
9.1.3 Medicinal Product name	24
9.1.4 Header	25
9.1.5 Manufacturer/Establishment (organisation)	25
9.1.6 Marketing authorisation	25
9.1.7 Packaged Medicinal Product	25
9.1.8 Pharmaceutical product	25
9.1.9 Ingredient	25
9.1.10 Clinical particulars	25
9.2 Medicinal Product	25

9.2.1	General	25
9.2.2	Detailed description of Medicinal Product information	26
9.3	Marketing authorisation	32
9.3.1	General	32
9.3.2	Detailed description of marketing authorisation information	33
9.4	Organisation	38
9.4.1	General	38
9.4.2	Detailed description of organisation information	38
9.5	Manufacturer/Establishment (organisation)	41
9.5.1	General	41
9.5.2	Detailed description of manufacturer/establishment (organisation) information	41
9.6	Packaged Medicinal Product, including manufactured item and device	42
9.6.1	General	42
9.6.2	Detailed description of Packaged Medicinal Product information	43
9.7	Ingredient, substance and strength	52
9.7.1	General	52
9.7.2	Detailed description of ingredients, substance and strength information	52
9.8	Pharmaceutical product and device	55
9.8.1	General	55
9.8.2	Detailed description of pharmaceutical product and device information	55
9.9	Clinical particulars	57
9.9.1	General	57
9.9.2	Detailed description for clinical particulars information	58
10	Identifying characteristics for Investigational Medicinal Products	62
10.1	General	62
10.2	Primary identifiers	62
10.2.1	General considerations	62
10.3	Investigational Medicinal Product Identifier (IMPID)	63
10.3.1	General considerations	63
10.3.2	IMPID code segments	63
10.4	Investigational Medicinal Product Package Identifier (IPCID)	64
10.4.1	General provisions	64
10.4.2	Package description code segment	64
10.5	Investigational Medicinal Product Batch Identifier (BAID1)	65
10.6	Investigational Medicinal Product Batch Identifier (BAID2)	65
11	Information for an Investigational Medicinal Product	65
11.1	General	65
11.2	Conceptual overview of the information for an Investigational Medicinal Product	65
11.2.1	General	65
11.2.2	Investigational Medicinal Product	66
11.2.3	Investigational Medicinal Product name	66
11.2.4	Header	66
11.2.5	Manufacturer/Establishment (organisation)	66
11.2.6	Clinical trial authorisation	67
11.2.7	Investigational Packaged Medicinal Product	67
11.2.8	Pharmaceutical product	67
11.2.9	Ingredient	67
11.2.10	Clinical particulars	67
11.3	Investigational Medicinal Product	67
11.3.1	General	67
11.3.2	Detailed description of Investigational Medicinal Product information	67
11.4	Clinical trial authorisation	70
11.4.1	General	70
11.4.2	Detailed description of clinical trial authorisation information	70
11.5	Manufacturer/Establishment (organisation)	72
11.6	Investigational Packaged Medicinal Product	72

11.7	Pharmaceutical product.....	72
11.7.1	General.....	72
11.7.2	Pharmaceutical product.....	73
11.7.3	Dosing and route of administration.....	73
11.8	Ingredient.....	73
11.9	Clinical particulars.....	74
11.10	PhPID sets.....	74
11.11	Device nomenclature.....	74
11.12	Device batch identifier.....	74
11.13	Physical characteristics.....	74
11.14	Other characteristics.....	74
Annex A	(normative) Full model — Authorised Medicinal Products detailed diagram.....	75
Annex B	(normative) Full model — Investigational Medicinal Products detailed diagram.....	76
Bibliography		77

Sample Document

get full document from standards.iteh.ai

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 215, *Health informatics*.

This second edition cancels and replaces the first edition (ISO 11615:2012), which has been technically revised.

Introduction

This document was developed in response to a worldwide demand for internationally harmonised specifications for Medicinal Products. It is part of a set of five ISO Standards and four ISO Technical Specifications which together provide the basis for the unique Identification of Medicinal Products (IDMP).

These sets of standards and technical specifications comprise:

- ISO 11615
- ISO/TS 20443;
- ISO 11616;
- ISO/TS 20451;
- ISO 11238;
- ISO/TS 19844;
- ISO 11239;
- ISO/TS 20440;
- ISO 11240.

These standards and technical specifications for the identification of Medicinal Products (IDMP) support the activities of medicines regulatory agencies worldwide by region. These include a variety of regulatory activities related to development, registration and life cycle management of Medicinal Products, as well as pharmacovigilance and risk management.

To meet the primary objectives of the regulation of medicines and pharmacovigilance, it is necessary to reliably exchange Medicinal Product information in a robust and consistent manner. The IDMP standards therefore support, at a minimum, the following interactions:

- regulatory medicines authority to regulatory medicines authority;
- pharmaceutical company to regulatory medicines authority;
- sponsor of a clinical trial to regulatory medicines authority;
- regulatory medicines authority to other stakeholders (as applicable);
- regulatory medicines authority to worldwide-maintained data sources.

The necessary messaging specifications are included as an integral part of the IDMP standards to secure the interactions above.

Unique identifiers produced in conformance with the IDMP standards are aimed at supporting applications where it is necessary to reliably identify and trace the use of Medicinal Products.

There are many terms in use to describe basic concepts in the regulatory, pharmaceutical and healthcare standards development domain for different purposes and in different contexts. The terms and definitions given in this document are to be applied for the concepts which are required to uniquely identify, characterise and exchange regulated Medicinal Products and associated information.

The terms and definitions adopted in this document are intended to facilitate the interpretation and application of legal and regulatory requirements.

This document has been developed in conjunction with the Common Product Model (CPM) and Structured Product Labelling (SPL) in HL7.

In the context of exchange of regulatory information, the purpose of this document is twofold:

- to specify data elements, structures and relationships between the data elements which are required to uniquely and with certainty identify Medicinal Products for human use;
- to specify definitions of terms for all data elements required to uniquely and with certainty identify Medicinal Products for human use.

In addition, reference to the use of other normative IDMP and messaging standards for Medicinal Product information is included in this document in order to support successful information exchange.

Sample Document

get full document from standards.iteh.ai

Health informatics — Identification of medicinal products — Data elements and structures for the unique identification and exchange of regulated medicinal product information

1 Scope

This document establishes definitions and concepts and describes data elements and their structural relationships, which are required for the unique identification and the detailed description of Medicinal Products.

Taken together, the standards listed in the Introduction define, characterise and uniquely identify regulated Medicinal Products for human use during their entire life cycle, i.e. from development to authorisation, post-marketing and renewal or withdrawal from the market, where applicable.

Furthermore, to support successful information exchange in relation to the unique identification and characterisation of Medicinal Products, the use of other normative IDMP messaging standards is included, which are to be applied in the context of this document.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 639-1, *Codes for the representation of names of languages — Part 1: Alpha-2 code*

ISO 3166-1:2013, *Codes for the representation of names of countries and their subdivisions — Part 1: Country codes*

ISO 8601, *Data elements and interchange formats — Information interchange — Representation of dates and times*

ISO 11238, *Health informatics — Identification of Medicinal Products — Data elements and structures for the unique identification and exchange of regulated information on substances*

ISO 11239, *Health informatics — Identification of Medicinal Products — Data elements and structures for the unique identification and exchange of regulated information on pharmaceutical dose forms, units of presentation, routes of administration and packaging*

ISO 11240, *Health informatics — Identification of Medicinal Products — Data elements and structures for the unique identification and exchange of units of measurement*

ISO 11616, *Health informatics — Identification of Medicinal Products — Data elements and structures for the unique identification and exchange of regulated pharmaceutical product information*

ISO/TS 19844, *Health informatics — Identification of Medicinal Products — Implementation guidelines for data elements and structures for the unique identification and exchange of regulated information on substances*

ISO/TS 20440, *Health informatics — Identification of Medicinal Products — Implementation guide for ISO 11239 data elements and structures for the unique identification and exchange of regulated information on pharmaceutical dose forms, units of presentation, routes of administration and packaging*

ISO/TS 20443, *Health informatics — Identification of Medicinal Products — Implementation guide for ISO 11615 data elements and structures for the unique identification and exchange of regulated Medicinal Product information*

ISO/TS 20451, *Health informatics — Identification of Medicinal Products — Implementation guide for ISO 11616 data elements and structures for the unique identification and exchange of regulated pharmaceutical product information*

ISO/IEC 5218, *Information technology — Codes for the representation of human sexes*

HL7 Version 3 Standard, Structured Product Labelling

3 Terms, definitions and abbreviated terms

3.1 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <http://www.iso.org/obp>
- IEC Electropedia: available at <http://www.electropedia.org/>

3.1.1

adjuvant

component that potentiates the immune response to an antigen and/or modulates it towards the desired immune response

3.1.2

administrable dose form

pharmaceutical dose form for administration to the patient, after any necessary transformation of the *manufactured items* (3.1.37) and their corresponding *manufactured dose forms* (3.1.36) has been carried out

Note 1 to entry: The administrable dose form is identical to the manufactured dose form in cases where no transformation of the manufactured item is necessary (i.e. where the manufactured item is equal to the pharmaceutical product).

Note 2 to entry: Administered dose form and pharmaceutical administrable dose form are synonyms of administrable dose form.

3.1.3

administration device

equipment intended for correct administration of the *Medicinal Product* (3.1.50)

Note 1 to entry: An administration device may be an integral part of an *immediate container* (3.1.27) or a closure.

[SOURCE: ENV 12610:1997]

3.1.4

allergen

material (3.1.47) of concern used as *ingredient* (3.1.28) or in a device capable of stimulating a type-I hypersensitivity or allergic reaction in atopic individuals

3.1.5

authorisation date

date when the authorisation was granted by a *Medicines Regulatory Agency* (3.1.56) following a specific regulatory activity

3.1.6**authorisation procedure**

formal procedure applied by a *Medicines Regulatory Agency* (3.1.56) to grant a *marketing authorisation* (3.1.40), to amend an existing one, to extend its duration or to revoke it

Note 1 to entry: The terms *authorisation procedure* and *marketing authorisation procedure* (3.1.43) are synonymous.

3.1.7**authorisation status**

phase of the *marketing authorisation* (3.1.40) during its life cycle

Note 1 to entry: The status indicates a particular moment in its life cycle.

3.1.8**batch**

specific quantity of a drug or other *material* (3.1.47) that is intended to have uniform character and quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of manufacture

3.1.9**batch number**

identifier (3.1.26) assigned to a specific *batch* (3.1.8) of a *Medicinal Product* (3.1.50) or item resulting from a manufacturing process at a specific point of time

3.1.10**characteristic**

abstraction of a property of an object

3.1.11**clinical trial**

investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an *Investigational Medicinal Product(s)* (3.1.31), and/or to study absorption, distribution, metabolism and excretion of *Investigational Medicinal Product(s)* with the object of ascertaining its safety and/or efficacy

Note 1 to entry: The terms *clinical trial* and *clinical study* are synonymous.

3.1.12**clinical trial authorisation**

approval given by a *Medicines Regulatory Agency* (3.1.56) to conduct a *clinical trial* (3.1.11) in a *region* (3.1.73)

3.1.13**class**

set of objects that share the same specifications of features, constraints, and semantics

3.1.14**combined pharmaceutical dose form**

two or more *manufactured items* (3.1.37) that are intended to be combined in a specific way to produce a single pharmaceutical product, and that includes information on the *manufactured dose form* (3.1.36) of each manufactured item and the *administrable dose form* (3.1.2) of the pharmaceutical product

3.1.15**common name**

official non-proprietary or generic name recommended by the World Health Organisation (WHO), or, if one does not exist, a non-proprietary name recommended by the *region* (3.1.73) within which the name is used

Note 1 to entry: Generic name and international non-proprietary name are synonymous of common name.

[SOURCE: WHO 46th Consultation on International Nonproprietary Names (INNs) for Pharmaceutical Substances]

3.1.16

container

item of packaging that is part of a *Medicinal Product* ([3.1.50](#)) and is used for storage, identification and/or transport of the components of the Medicinal Product

3.1.17

contraindication

situations where the *Medicinal Product* ([3.1.50](#)) shall not be given for safety reasons

3.1.18

controlled vocabulary

finite set of values that represent the only allowed values for a data item

Note 1 to entry: The allowed values can be codes, text or numeric.

[SOURCE: CDISC Clinical Research Glossary V10.0, 2016]

3.1.19

datatype

set of distinct values, characterised by properties of those values, and by operations on those values

[SOURCE: ISO 11404:2007, 3.12]

3.1.20

device listing number

number assigned by a *Medicines Regulatory Agency* ([3.1.56](#)) during registration and/or listing to all devices in commercial distribution, regardless of pre-market authorisation requirements, per regional registration and listing requirements

3.1.21

device model number

identifier ([3.1.26](#)) assigned by a medical device *manufacturer* ([3.1.38](#)) to a particular design or version of a *medical device* ([3.1.49](#))

3.1.22

distributor

organisation in possession of a license covering the procuring, holding, supplying or exporting of *Medicinal Products* ([3.1.50](#)), apart from supplying Medicinal Products to the public

Note 1 to entry: This is applicable to “wholesale distribution of Medicinal Products”.

3.1.23

dose

specified quantity of a medicine, to be taken at one time or at stated intervals

3.1.24

dose form

physical manifestation of a *Medicinal Product* ([3.1.50](#)) that contains the active *ingredient(s)* ([3.1.28](#)) and/or inactive ingredient(s) that are intended to be delivered to the patient

Note 1 to entry: Dose form, dosage form and pharmaceutical dose form are synonymous. “Pharmaceutical dose form” can refer to the *administrable dose form* ([3.1.2](#)) or the *manufactured dose form* ([3.1.36](#)).

3.1.25**Global Trade Item Number****GTIN**

GS1 unique *identifier* (3.1.26) of items that are traded [e.g. pharmaceuticals, *medical devices* (3.1.49)] in the supply chain

Note 1 to entry: A GTIN is used to identify any item upon which there is a need to retrieve predefined information and that may be priced, ordered or invoiced at any point in any supply chain. GTINs may be 8, 12, 13 or 14 digits in length.

3.1.26**identifier**

description that is sufficient to represent an object in a given environment

Note 1 to entry: In the context of this document, this is a list of identifying *characteristics* (3.1.10) that together unambiguously identify a *Medicinal Product* (3.1.50), pharmaceutical product, *substance* (3.1.80), *specified substance* (3.1.77), *route of administration* (3.1.76), pharmaceutical dose form or any other element which requires to be uniquely identified.

[SOURCE: ENV 12610:1997]

3.1.27**immediate container**

packaging in which a *manufactured item* (3.1.37) or pharmaceutical product is contained and with which it is in direct contact

Note 1 to entry: An immediate container can be fitted with or have integrated into it an *administration device* (3.1.3) and/or closure. A pharmaceutical dose form can fulfil the role of an immediate container, e.g. a capsule containing a powder for inhalation; the capsule in this case is not a *container* (3.1.16). An alternative, compatible definition of immediate container ("immediate packaging") is given in Directive 92/27/EEC.

[SOURCE: ENV 12610:1997]

3.1.28**ingredient**

material (3.1.47) used in the preparation of a medicinal/pharmaceutical product

Note 1 to entry: The ingredient is part of a *Medicinal Product* (3.1.50), either alone or in combination with other ingredients. The ingredient is also a component of a pharmaceutical product. Ingredient is equal to a *substance* (3.1.80) with the indication of the specific role it is playing in the product.

3.1.29**intermediate packaging**

container (3.1.16) between the *outer packaging* (3.1.57) and the *immediate container* (3.1.27)

3.1.30**invented name**

proprietary name for a *Medicinal Product* (3.1.50) as authorised by a *Medicines Regulatory Agency* (3.1.56) in a *region* (3.1.73)

Note 1 to entry: The term invented name is synonymous with trade name and with brand name for a Medicinal Product.

3.1.31**Investigational Medicinal Product**

pharmaceutical product or combination of pharmaceutical products or placebo(s) being tested or used as a reference in a *clinical trial* (3.1.11), including products already with a *marketing authorisation* (3.1.40) but used or assembled (packaged) in a way different from the authorised form, used for an unauthorised indication, or used to gain further information about the authorised form

3.1.32

Investigational Medicinal Product Identifier

unique *identifier* (3.1.26) allocated to an *Investigational Medicinal Product* (3.1.31) supplementary to any existing identifier as ascribed by a *Medicines Regulatory Agency* (3.1.56) in a *region* (3.1.73)/*jurisdiction* (3.1.34) or a sponsor of a *clinical trial* (3.1.11)

Note 1 to entry: This is an alphanumeric text field.

Note 2 to entry: This is for indexing purposes and to contribute to improving patient safety by allowing for the unique identification of *Medicinal Products* (3.1.50) worldwide.

3.1.33

Investigational Medicinal Product Package Identifier

unique *identifier* (3.1.26) allocated to an Investigational Packaged Medicinal Product at package level supplementary to any existing identifier as ascribed by a *Medicines Regulatory Agency* (3.1.56) in a *region* (3.1.73)/*jurisdiction* (3.1.34) or a sponsor of a *clinical trial* (3.1.11)

Note 1 to entry: This is for indexing purposes and to contribute to improving patient safety by allowing for the unique identification of *Medicinal Products* (3.1.50) worldwide.

3.1.34

jurisdiction

geographical area within a country/*region* (3.1.73) or subject matter to which the *Medicines Regulatory Agency* (3.1.56) applies

3.1.35

legal status of supply

regional/jurisdictional rule as to whether a *Medicinal Product* (3.1.50) is subject to a medical prescription before it may be supplied to a patient or consumer

3.1.36

manufactured dose form

pharmaceutical dose form of a *manufactured item* (3.1.37) as manufactured and, where applicable, before transformation into the pharmaceutical product

Note 1 to entry: The manufactured dose form is identical to the *administrable dose form* (3.1.2) in cases where no transformation of the manufactured item is necessary (i.e. where the manufactured item is equal to the pharmaceutical product).

3.1.37

manufactured item

qualitative (3.1.70) and *quantitative composition* (3.1.71) of a product as contained in the packaging of the *Medicinal Product* (3.1.50) as put on the market or *Investigational Medicinal Product* (3.1.31) as used in a *clinical trial* (3.1.11)

Note 1 to entry: A *Medicinal Product* (3.1.50) may contain one or more manufactured items. In many instances, the manufactured item is equal to the pharmaceutical product. However, there are instances where the manufactured item(s) undergo a transformation before being administered to the patient (as the pharmaceutical product) and the two are not equal.

3.1.38

manufacturer

organisation that holds the authorisation for the manufacturing process

Note 1 to entry: Establishment is a synonym of manufacturer.

3.1.39**manufacturing authorisation**

authorisation provided by a *Medicines Regulatory Agency* (3.1.56) to manufacture *Medicinal Products* (3.1.50) within a *region* (3.1.73)

Note 1 to entry: Such authorisation may be required for both total and partial manufacture and for the various processes of dividing up, packaging or presentation. However, such authorisation may not be required for preparation, dividing up, changes in packaging or presentation where these processes are carried out, solely for retail supply, by pharmacists in dispensing pharmacies or by persons legally authorised in a region to carry out such processes.

3.1.40**marketing authorisation**

authorisation issued from a *Medicines Regulatory Agency* (3.1.56) that allows a *Medicinal Product* (3.1.50) to be placed on the market

3.1.41**marketing authorisation holder**

organisation that holds the authorisation for marketing a *Medicinal Product* (3.1.50) in a *region* (3.1.73)

3.1.42**marketing authorisation number**

identifier (3.1.26) assigned by a *Medicines Regulatory Agency* (3.1.56) to a *Medicinal Product* (3.1.50)

3.1.43**marketing authorisation procedure**

formal procedure applied by a *Medicines Regulatory Agency* (3.1.56) to grant a *marketing authorisation* (3.1.40), amend an existing one, extend its duration or to withdraw it

Note 1 to entry: Marketing authorisation procedure and *authorisation procedure* (3.1.6) are synonymous.

3.1.44**marketing start date**

date when the authorised *Medicinal Product* is marketed in a *region* (3.1.73)

Note 1 to entry: The date of actual marketing of a *Medicinal Product* (3.1.50) is always after a *marketing authorisation* (3.1.40) has been granted by a *Medicines Regulatory Agency* (3.1.56).

3.1.45**marketing stop date**

date when the marketing of the authorised *Medicinal Product* is stopped in a *region* (3.1.73)

3.1.46**marketing status**

when a *Medicinal Product* (3.1.50) is actually put on the market or is no longer available in a country or *jurisdiction* (3.1.34)

3.1.47**material**

substance (3.1.80) or *specified substance* (3.1.77) of which a certain packaging or device is made

Note 1 to entry: This applies to a *Medicinal Product* package item [*container* (3.1.16)], package (component) and device.

3.1.48**measurement point**

physical location on an *administration device* (3.1.3) where the quantity of the medication being delivered is measured